We newly prepared lipopolyplexes containing N-lauroylsarcosine ( 
Introduction
Gene delivery to the lung is being investigated for a number of inherited and acquired disorders, such as cystic fibrosis [1] , emphysema [2] , asthma [3] and certain types of lung cancer [4, 5] , and is also being considered as a means of vaccination [6] .
The feasibility of intranasal and intratracheal approaches in gene delivery to the lung has been supported by many studies [7, 8] ; however, airway-directed gene delivery is not simple because the lung has evolved both physical and immunologic barriers [9] .
Direct gene delivery into the lung via intranasal or intratracheal routes is likely to be more challenging in patients with diseases such as cystic fibrosis characterized by a lung pathology with thick mucus production [10, 11] . Pulmonary gene delivery after systemic administration is expected as an alternative route for plasmid DNA (pDNA)
complexes.
In the previous study, we demonstrated the strong potential of a lipopolyplex (ternary complex of pDNA, cationic polymer, and cationic lipid) consisting of polyethylenimine (PEI) and N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethlylammonium chloride (DOTMA) as an efficient gene delivery vector [12] . We preliminary found that a lipoplex (complex of pDNA and cationic liposomes) containing N-lauroylsarcosine (LS), which is a low-toxic bio-degradable detergent, showed high transgene efficiency in the lung after intravenous administration. LS is readily metabolized by humans to sarcosine and corresponding fatty acids [13] . Therefore, we newly prepared a hybrid vector, lipopolyplexes composed of PEI, DOTMA and LS, for pulmonary gene delivery via the systemic route. We investigated the transgene efficiency and safety of the new hybrid vector under in vitro and in vivo conditions, and analyzed the contribution of LS molecules for transgene efficiency. Lipopolyplexes 4 containing LS showed markedly high transgene efficiency in the lung after intravenous administration although they showed no cytotoxicity and no aggregation with erythrocytes. We discovered for the first time that LS molecules contributed to transgene efficiency of lipopolyplexes in the lung at 76.7% of the contribution index.
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Materials and methods
Chemicals
The structure of LS is shown in Figure 1 . antibiotics (penicillin 100 U/ml and streptomycin 100 μg/ml) and other culture reagents were obtained from GIBCO BRL (Grand Island, NY, USA). Phosphate-buffered saline (PBS) was prepared by mixing isotonic phosphate buffer (pH 7.4) with an equal volume of saline. WST-1 (2-(4-Iodophenyl)-3-(4-nitrophenyl)-2H-tetrazolium, monosodium salt) and 1-methoxy PMS (1-methoxy-5-methylphenazinium methylsulfate) were obtained from Dojindo Laboratories (Kumamoto, Japan). All other chemicals were of reagent grade and used as obtained commercially.
Construction of pDNA
pCMV-luciferase was constructed by subcloning the HindIII/Xbal firefly luciferase 6 cDNA fragment from the pGL3-control vector (Promega, Madison, WI, USA) into the polylinker of the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA). pDNA was amplified using a EndoFree ® Plasmid Giga Kit (QIAGEN GmbH, Hilden, Germany).
pDNA was dissolved in 5% dextrose solution and stored at -80 o C until analysis. The pDNA concentration was measured at 260 nm absorbance and adjusted to 1 mg/ml.
Preparation of polyplex and lipopolyplex
The theoretical charge ratio of pDNA/PEI complexes was calculated as the molar ratio of PEI nitrogen to pDNA phosphate. An appropriate amount of stock PEI solution (pH 7.4) was mixed with a diluted solution of pDNA (1 mg/ml) by pipetting thoroughly to prepare polyplexes (complex of pDNA and cationic polymer) at a charge ratio 2 (polyplex 2P) or 8 (polyplex 8P). To prepare lipopolyplexes, the theoretical charge ratio of DOTMA to pDNA was calculated as the molar ratio of DOTMA nitrogen to pDNA phosphate. The theoretical charge ratio of LS to pDNA was calculated as the molar ratio of LS carboxylate to pDNA phosphate. DOTMA ethanol solution was added to polyplex 2P at a charge ratio of DOTMA/pDNA 2 to preparing the lipopolyplex 2P-2D. LS ethanol solution was added to lipopolyplex 2P-2D at a charge ratio of LS/pDNA 2 and 4 to prepare lipopolyplex 2P-2D-2L and 2P-2D-4L.
Physicochemical properties and gel retardation of lipopolyplexes
The particle size and zeta potential of the polyplexes and lipopolyplexes were measured with a Zetasizer Nano ZS (Malvern Instruments, Ltd., UK). The 5 μl aliquots of complex solution containing 1 μl pDNA was mixed with 1 μl of loading 7 buffer (30% glycerol and 0.2% bromophenol blue) and was loaded onto a 0.6% agarose gel. Electrophoresis (i-Mupid J®, Cosmo Bio, Tokyo, Japan) was carried out at 50 V in running buffer solution (40 mM Tris/HCl, 40 mM acetic acid, and 1mM EDTA).
The retardation of complexes was visualized with ethidium bromide staining.
In vitro gene expression experiments
The 
Erythrocytes aggregation assay
Male ddY mice (5-6 weeks old) were purchased from Japan SLC (Shizuoka, Japan).
Erythrocyte suspension was prepared from ddY mice by centrifugation at 4 o C and 3,000 × g (Kubota 3700, Kubota, Tokyo, Japan) for 15 min and washed three times with PBS. The 2% erythrocytes suspension (20 μl) was incubated with an equal 9 volume of polyplex and lipopolyplexes containing 2 μg of pDNA for 30 min.
Aggregation was observed by optical microscopy (400 × magnification).
In vivo gene expression experiments
Animal care and experimental procedures were performed in accordance with the Guidelines for Animal Experimentation of Nagasaki University with approval from the Institutional Animal Care and Use Committee. Polyplex and lipopolyplexes containing 40 μg of pDNA were injected into the tail vein of mice (200 μl per mouse), which were sacrificed 6 h after injection. The liver, kidney, spleen, heart, and lung were dissected and homogenized with lysis buffer using a homogenizer (Omni TH-115, Yamato Scientific Co., Ltd., Tokyo, Japan). After centrifugation of the homogenates at 21,880 × g for 5 min, the supernatants were used for luciferase assay.
Luciferase assay
A 10 μl lysate sample was mixed with 50 μl of luciferase assay buffer (Picagene, Toyo Ink, Tokyo, Japan) and the light produced was immediately measured using a 
Statistical analysis
Statistical analysis was performed using Scheffe's test for multiple comparison. p < 0.05 was considered significant.
Data analysis for optimal formulation
The optimum formulation was estimated using a simultaneous optimization technique in which a multivariate spline interpolation (MSI) was incorporated. The contribution of hybrid vector components to transgene efficiency was also estimated according to the optimization. We carried out additional in vivo experiments (Table 1) and added the data for optimization. A two-factor composite second-order spherical experimental design was employed to select model formulations. The data measured for model formulations were analyzed with a computer program, dataNESIA (Yamatake Corp., Tokyo, Japan). MSI has recently been recognized as a superior method for high precision modeling of multi-dimensional data points [14] . MSI is basically a boundary element method [15] . Green functions are used to interpolate the minimum curvature of multi-dimensional data points [16] . Observational data include experimental error.
To avoid problems with estimation, the multi-dimensional data surface, including experimental error, is estimated as the sum of interpolation with a Green function in a linear polynomial equation (thin-plate approximation) [16] . The smoothing parameter, which is the ratio of Green function interpolation and thin-plate approximation, is automatically estimated using a generalized cross-validation technique. The optimum formulation and the contribution of hybrid vector components to transgene efficiencies were estimated based on the standardized Euclidian distance described previously [17] .
As a matter of convenience for analysis, contribution ratios were not calculated in the kidney and heart. 
Results
Physicochemical properties of lipopolyplexes
The particle size and zeta potential of lipopolyplexes containing LS were measured with Zetasizer Nano ZS and are shown in Table 2 . Data of polyplex 2P and lipopolyplex 2P-2D were reported in the previous paper [12] . The addition of cationic lipid, DOTMA, to polyplex 2P decreased the particle size and increased the zeta The gel retardation assay was performed to examine complex formations of the polyplex and lipopolyplexes and is shown in Fig. 2 . Lipopolyplex 2P-2D, 2P-2D-2L, and 2P-2D-4L were found to tightly hold pDNA.
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In vitro transgene efficiency of lipopolyplexes
Cytotoxicity of lipopolyplexes
Cytotoxicity of lipopolyplexes containing LS was determined by WST-1 assay in the presence of FBS and is shown in Fig. 4 . Polyplex 2P, 8P and lipopolyplex 2P-2D, 2P-2D-2L and 2P-2D-4L did not show any significant cytotoxicity. In the preliminary experiment, commercially available lipofectin showed 39.8% of cell viability. The 15 viability of cells treated with polyplexes and lipopolyplexes was more than 90% of control cells.
Erythrocyte aggregation assay
Erythrocyte aggregation assay was performed to examine the interaction of polyplexes and lipopolyplexes with mouse erythrocytes and the results are shown in Fig.   5 . Polyplex 2P had slight aggregation with erythrocytes ( Fig. 5A ) and partial aggregation was found in lipopolyplex 2P-2D (Fig. 5B) . Polyplex 8P showed strong aggregation (data not shown). In contrast, lipopolyplexes containing LS did not show any aggregation (Fig. 5C, D) . 16 
In vivo transgene efficiency of polyplexes and lipopolyplexes
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In vivo transgene efficiency of lipopolyplexes containing LS were examined in ddY male mice (Fig. 6) . At 6 h after intravenous injection of lipopolyplexes into mice, luciferase activities were measured in several tissues. In the previous study, we reported that polyplex 8P and lipopolyplex 2P-2D showed high transgene efficiency, as high as lipofectin, in the spleen, liver, and lung, although little transgene efficiency was observed by polyplex 2P [12] . Lipopolyplexes containing LS showed high transgene efficiency compared to lipopolyplex 2P-2D. In particular, in the lung, lipopolyplex 2P-2D-2L was found to have significantly higher expression than lipopolyplex 2P-2D.
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Formulation optimization
Based on the in vivo results, we estimated the optimum formulation of lipopolyplexes with high transgene efficiency as a pharmaceutical formulation. In this case, the study was performed using model formulations prepared according to the two-factor spherical second-order composite experimental design. We carried out additional in vivo experiments and added data for optimization. The data measured for model formulations were analyzed with a computer program, dataNESIA. MSI has recently been recognized as a superior method for the high precision modeling of multi-dimensional data points [14] . The three-dimensional diagram of the contribution ratio to the transgene efficiency in the lung is shown in Fig. 7 . The optimal ratios of pDNA, PEI, DOTMA, and LS as lipopolyplex were 1.0: 11. 
Discussion
The success of gene therapy highly depends on the development of an effective and secure delivery vector. The viral vector is highly effective and is employed for clinical trials although some severe adverse events in clinical trials have given great concern regarding its safety [18] . On the other hand, non-viral vectors have safety advantages; much less immunotoxicity, clear structure, and easy modeling [19, 20] . The formation of pDNA-vector complex is an important factor contributing to transgene efficiency. In the previous study, we investigated the strong potential of lipopolyplex consisting of PEI and DOTMA for efficient gene delivery [12] . We preliminary found that lipoplex containing LS had high transgene efficiency in the lung after intravenous administration. Based on these results, we newly prepared a hybrid vector, lipopolyplexes composed of PEI, DOTMA and LS, for pulmonary gene delivery via the systemic route.
We already reported that the particle size of polyplex 2P was remarkably reduced by DOTMA addition, indicating strong pDNA compaction. In the previous study, we added DOTMA to polyplexes and did not find any liposomal shape by transmission electron microscopy [12] . The particle size of complexes is an important factor to control cellular uptake because small particles should more easily enter cells via an have several uptake mechanisms according to organs. However, the mechanism for the lung directivity of lipopolyplexes containing LS was not clear. The LS structure was similar to that of lauric acid. As the results of the lipopolyplexes containing lauric acid, however, they showed much lower transgene efficiencies than lipopolyplex 2P-2D-2L in the preliminary in vivo experiment (4.52 × 10 6 ± 2.75 × 10 6 RLU/g tissue in the lung). So, we suggest the specific uptake of lipopolyplexes containing LS by pulmonary cells via recognition of LS structure. On the other hand, the low cytotoxicity and erythrocyte aggregation of lipopolyplex containing LS must be due to low zeta potential on the particle surface by addition of LS. The complexes with low zeta potential decrease the electrostatic interaction with the cellular membrane.
In order to confirm the contribution of LS to the lung directivity, we carried out additional in vivo experiments (Table 1 ) and analyze all data for designing the optimum formulation.
The optimum formulation was estimated using a simultaneous optimization technique in which MSI was incorporated. As a result of this analysis, we found that PEI and DOTMA contributed to the high transgene efficiency of the complex composed of LS, DOTMA, and PEI in the liver and spleen. In contrast, in the lung, the high transgene efficiency of this complex depended on the contribution of LS, which was 76.7% of the contribution index. These results suggest that lipopolyplexes containing LS are a useful gene delivery vector with lung directivity.
Complexes with a strong positive charge showed high transgene efficiency because of their strong interaction with cell membranes; however, the strong positive charge on the complexes aggregates with erythrocytes [31] and is eliminated rapidly from the blood. The large aggregates of lipoplexes with erythrocytes may cause clinical problems because of microinfarction, causing tissue ischemia and possible myocardial damage [32] ; however, we discovered that lipopolyplexes containing LS, which showed a low positive charge, had high transgene efficiency and low toxicity under in vitro and in vivo conditions. In particular, the addition of LS to lipopolyplex largely increased transgene efficiency in the lung. Further study is necessary to examine the mechanism of their high transgene efficiency.
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Conclusion
We newly prepared lipopolyplexes containing LS as a hybrid vector for pulmonary gene delivery via the systemic route. The lipopolyplexes containing LS had high transgene efficiency in HepG2 cells without any cytotoxicity. They also showed no aggregation with erythrocytes and markedly high transgene efficiency in the lung after their intravenous administration in mice. We discovered that LS molecules contributed to the high transgene efficiency in the lung as 76.7% of the contribution index.
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